Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT database

21 Nov 2024

Abstract excerpt

BACKGROUND: Since homologous recombination deficiency (HRD) is relatively uncommon in pancreatic cancer (PC), its impact on time-to-treatment failure (TTF) among patients undergoing systemic chemotherapy for unresectable and recurrent PC remains uncertain. METHODS: Among patients with unresectable and recurrent PC enrolled in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database by July 2023,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39570378
DOI: 10.1007/s00535-024-02173-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association between homologous recombination deficiency and time to treatment failure to platinum-based chemotherapy for pancreatic cancer by using the C-CAT databasePMID 39570378Read ↗

Platinum-based chemotherapy for pancreatic cancer: impact of mutations in the homologous recombination repair and Fanconi anemia genesSemantic proximity Read ↗

Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy durationSemantic proximity Read ↗

Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.Semantic proximity Read ↗

Core Homologous Recombination Mutations and Improved Survival in Nonpancreatic GI Cancers.Semantic proximity Read ↗

Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies.Semantic proximity Read ↗

Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity.Semantic proximity Read ↗

Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in TaiwanSemantic proximity Read ↗

Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor ProgramSemantic proximity Read ↗

Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer.Semantic proximity Read ↗

Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancerSemantic proximity Read ↗

Prevalence of Homologous Recombination–Related Gene Mutations Across Multiple Cancer TypesSemantic proximity Read ↗

Whole Genome Landscape Analysis of Homologous Recombination Deficiency in a Pan-Cancer CohortSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.